CompanyIVVDNasdaqNew Haven, CT

Invivyd, Inc.

Invivyd develops monoclonal antibodies against viral infectious diseases, beginning with SARS-CoV-2.

SEC EDGAR ClinicalTrials.gov invivyd.com

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

Invivyd reports VYD2311 topline safety edge over mRNA COVID vaccine in LIBERTY trial

Sep 29Clinical readoutInvivyd, Inc.

Invivyd names Chairman Marc Elia as CEO, adds board member ahead of VYD2311 data

Sep 1PeopleInvivyd, Inc.

August 2026

Invivyd completes enrollment in two VYD2311 pivotal trials, reports Q2 2026 results

Aug 13Quarterly updateInvivyd, Inc.